natgillin/translations-raw huggingface dataset:
Efavirenz 600 mg QD (atazanavir 400 mg QD med
Efavirenz 600 mg QD (atazanavir 400 mg QD with
atazanavir (aften): alle administreret
atazanavir (pm): all administered
↔1, 06 * / **
↔ 1.06*/ **
↔1, 09 * / **
↔ 1.09*/ **
↔1, 12 * / **
↔ 1.12*/ **
4. 4)
section 4.4)
ritonavir 200 mg QD)
ritonavir 200 mg QD)
(0, 90; 1, 26)
(0.90, 1.26)
(0, 95; 1, 26)
(0.95, 1.26)
(0, 84; 1, 49)
(0.84, 1.49)
* Sammenlignet med REYATAZ 300 mg/ ritonavir 100 mg én gang dagligt om aftenen uden efavirenz.
* When compared to REYATAZ 300 mg/ ritonavir 100 mg once daily in the evening without efavirenz.
Dette fald i atazanavir Cmin, kan påvirke effekten af atazanavir negativt.
This decrease in atazanavir Cmin, might negatively impact the efficacy of atazanavir.
Interaktionsmekanismen for efavirenz/ atazanavir er CYP3A4- induktion. ** baseret på historisk sammenligning.
The mechanism of efavirenz/ atazanavir interaction is CYP3A4 induction. ** based on historical comparison.
(atazanavir 400 mg QD med
(atazanavir 400 mg QD with ritonavir 100 mg QD) study
(1, 17; 1, 36)
atazanavir
(1, 11; 1, 32)
(1.17, 1.36) ↓ 0.81*
(1, 25; 1, 47)
(1.11, 1.32) ↔ 1.02*
administration af
(1.25, 1.47) ↓ 0.41*
ritonavir 100 mg QD).
nevirapine with REYATAZ/ ritonavir is
Undersøgelse udført med HIV -
conducted in HIV infected
(0, 65; 1, 02)
(0.65, 1.02)
(0, 85; 1, 24)
(0.85, 1.24)
(0, 27; 0, 60)
(0.27, 0.60)
REYATAZ /
not recommended (see
inficerede patienter Antibiotika
patients Antibiotics
* Sammenlignet med REYATAZ 300 mg/ ritonavir 100 mg uden nevirapin.
* When compared to REYATAZ 300 mg and ritonavir 100 mg without nevirapine.
Interaktionsmekanismen for nevirapin/ atazanavir er CYP3A4- induktion.
The mechanism of nevirapine/ atazanavir interaction is CYP3A4 induction.
Clarithromycin 500 mg BID
Clarithromycin 500 mg BID
↑1, 94 ↑1, 50 ↑2, 60 clarithromycin
↑ 1.94 ↑ 1.50 ↑ 2.60 clarithromycin
Der kan ikke gives
No recommendation
(1, 75; 2, 16) (1, 32; 1, 71) (2, 35; 2, 88) 14- OH ↓0, 30 ↓0, 28 ↓0, 38
(1.75, 2.16) (1.32, 1.71) (2.35, 2.88) 14-OH ↓ 0.30 ↓ 0.28 ↓ 0.38
anbefaliner vedrørende dosisreduktion; der bør
regarding dose reduction can be made;
clarithromycin (0, 26; 0, 34) (0, 24; 0, 33) (0, 34; 0, 42)
clarithromycin (0.26, 0.34) (0.24, 0.33) (0.34, 0.42)
derfor udvises forsigtighed hvis
therefore, caution should be exercised if
↑1, 28 ↔1, 06 ↑1, 91 atazanavir (1, 16; 1, 43) (0, 93; 1, 20) (1, 66; 2, 21)
↑ 1.28 ↔ 1.06 ↑ 1.91 atazanavir (1.16, 1.43) (0.93, 1.20) (1.66, 2.21)
REYATAZ / ritonavir administreres
REYATAZ/ ritonavir is co-administered with
Dosisreduktion i clarithromycin kan medføre subterapeutiske koncentrationer af 14- OH clarithromycin.
A dose reduction of clarithromycin may result in subtherapeutic concentrations of 14-OH clarithromycin.
Interaktionsmekanismen for clarithromycin/ atazanavir er CYP3A4- hæmning.
The mechanism of the clarithromycin/ atazanavir interaction is CYP3A4 inhibition.
samtidig med clarithromycin.
clarithromycin.
Ketoconazol 200 mg QD (atazanavir 400 mg QD)
Ketoconazole 200 mg QD (atazanavir 400 mg QD)
Der er ikke set signifikant påvirkning af atazanavirkocentrationen.
No significant effect on atazanavir concentrations was observed.
Ketoconazol og itraconazol bør anvendes med
Ketoconazole and itraconazole should be used cautiously with
Itraconazol er som ketoconazol en potent hæmmer såvel som et substrat af CYP3A4.
Itraconazole, like ketoconazole, is a potent inhibitor as well as a substrate of CYP3A4.
REYATAZ / ritonavir.
REYATAZ/ ritonavir.
Samtidig administration af
High doses of ketoconazole and
Samtidigt administrerede
7 Co-administered medicinal
voriconazol og
itraconazole (> 200 mg/ day) are not recommended.
Effekt af samtidig administration af oral voriconazol og lav- dosis (100 mg) oral ritonavir er undersøgt hos raske frivillige.
The effect of co-administration of oral voriconazole and low dose (100 mg) oral ritonavir was investigated in healthy volunteers.
Lave doser af ritonavir (100 mg BID) reducerede Cmax og AUC for voriconazol (90% KI) med i gennemsnit henholdsvis 24% (↓9% til ↓36%) og 39% (↓22% til ↓52%).
Low doses of ritonavir (100 mg BID) decreased the Cmax and AUC of voriconazole (90% CI) by an average of 24% (↓ 9% to ↓ 36%) and 39% (↓ 22% to ↓ 52%), respectively.
Administration af voriconazol medførte et mindre fald i steady- state Cmax og AUC for ritonavir (90% KI) med i gennemsnit henholdsvis 24% (↓6% til ↓39%) og 14% (↓26% til ↑1%).
Administration of voriconazole resulted in a minor decrease in steady state Cmax and AUC of ritonavir (90% CI) with an average of 24% (↓ 6% to ↓ 39%) and 14% (↓ 26% to ↑ 1%), respectively.
REYATAZ / ritonavir frarådes, med mindre det vurderes, at fordel/ risiko- forholdet for patienten berettiger brug af voriconazol (se pkt.
not recommended unless an assessment of the benefit/ risk to the patient justifies the use of voriconazole (see section 4.4).
Patienterne bør monitoreres omhyggeligt for bivirkninger og/ eller manglende effekt ved samtidig administration af voriconazol og REYATAZ / ritonavir.
Patients should be carefully monitored for adverse events and/ or loss of efficacy during the co-administration of voriconazole and REYATAZ/ ritonavir.
Fluconazol 200 mg QD (atazanavir 300 mg og ritonavir 100 mg QD) Antimykobakterielle midler
Fluconazole 200 mg QD (atazanavir 300 mg and ritonavir 100 mg QD) Antimycobacterial
Atazanavir - og fluconazolkoncentrationer ændredes ikke signifikant ved samtidig administration af REYATAZ/ ritonavir og fluconazol.
Atazanavir and fluconazole concentrations were not significantly modified when REYATAZ/ ritonavir was co-administered with fluconazole.
Dosisjustering er ikke nødvendig for REYATAZ / ritonavir og fluconazol.
No dosage adjustments are needed for REYATAZ/ ritonavir and fluconazole.
↑1, 15 ↑1, 34 ↑1, 13
↑ 1.15 ↑ 1.34 ↑ 1.13
En reduktion i
A rifabutin dose
atazanavir (0, 98; 1, 34) (1, 14; 1, 59) (0, 68; 1, 87)
atazanavir (0.98, 1.34) (1.14, 1.59) (0.68, 1.87)
rifabutin- dosis på op til 75% (fx 150 mg hver
reduction of up to 75% (eg, 150 mg every
↑2, 10 ↑1, 18 ↑3, 43 rifabutin
↑ 2.10 ↑ 1.18 ↑ 3.43 rifabutin
anden dag eller
other day or 3 times
(atazanavir 600 mg QD) Dette er ikke den anbefalede terapeutiske dosis for
(atazanavir 600 mg QD) This is not the recommended therapeutic dose of atazanavir.
(1, 57; 2, 79) (0, 94; 1, 48) (1, 98; 5, 96) 25- O- desacetyl - ↑22, 01 * ↑8, 20 * ↑75, 6 *
(1.57, 2.79) (0.94, 1.48) (1.98, 5.96) 25-O-desacetyl- ↑ 22.01* ↑ 8.20* ↑ 75.6* rifabutin (15.97, 30.34) (5.90, 11.40) (30.1, 190.0) * When compared to rifabutin 300 mg QD.
Interaktionsmekanismen for rifabutin og atazanavir er CYP3A4 - hæmning.
The mechanism of rifabutin and atazanavir interaction is CYP3A4 inhibition
ritonavir.
per week) is recommended when rifabutin is administered with REYATAZ/ ritonavir.
Dosisjustering for REYATAZ / ritonavir er ikke nødvendig.
No dose adjustment is needed for REYATAZ/ ritonavir.
Rifampicin SYREHÆMMENDE MIDLER H2- receptorantagonister
Rifampicin ACID REDUCING AGENTS H2-Receptor antagonists
Rifampicin er en kraftig CYP3A4- induktor og er vist at reducere AUC af atazanavir med 72%, hvilket kan medføre virologisk svigt og udvikling af resistens.
Rifampicin is a strong CYP3A4 inducer and has been shown to cause a 72% decrease in atazanavir AUC which can result in virological failure and resistance development.
Der er ved forsøg på at kompensere for den nedsatte optagelse ved at øge dosis af REYATAZ, eller andre proteasehaemmere med ritonavir, set høj frekvens af leverreaktioner.
During attempts to overcome the decreased exposure by increasing the dose of REYATAZ or other protease inhibitors with ritonavir, a high frequency of liver reactions was seen.
4. 3).
The combination of rifampicin and REYATAZ with concomitant low-dose ritonavir is contraindicated (see section 4.3).
Famotidin 40 mg BID
Famotidine 40 mg BID
↓ 0, 82 ↓0, 86 ↓0, 72
↓ 0.82 ↓ 0.86 ↓ 0.72 atazanavir
Dosisjustering af
No dosage adjustment
atazanavir (atazanavir 300 mg QD med
(atazanavir 300 mg QD with ritonavir 100 mg QD)
Selvom det ikke er undersøgt, forventes lignende resultater med andre H2- receptorantagonister.
(0.75, 0.89) (0.79, 0.94) (0.64, 0.81) Although not studied, similar results are expected with other H2-receptor antagonists.
Relevansen af disse data for HIV- inficerede patienter er ukendt, da intragastrisk pH kan være højere i denne population.
The relevance of these data for HIV infected patients is unknown since the intragastric pH may be higher in this population.
Omfanget af denne effekt kan derfor være større.
Therefore, the magnitude of this effect may be more pronounced.
Interaktionsmekanismen er nedsat opløselighed af atazanavir, fordi det intragastriske pH stiger med H2- blokkere.
The mechanism of interaction is decreased solubility of atazanavir as intra- gastric pH increases with H2 blockers.
er ikke nødvendig ved samtidig administration med H2- receptorantagonist, givet som daglig enkeltdosis med mad.
of REYATAZ/ ritonavir is required when co-administered with an H2-receptor antagonist, all as a single daily dose with food.
Fald i atazanavir - koncentrationen kan undgås ved tidsmæssig adskillelse af REYATAZ og H2- receptorantagonis - ten på følgende måde:
Reductions in atazanavir concentrations may be avoided by temporal separation of REYATAZ and an H2-receptor antagonist as follows:
REYATAZ 300 mg/ ritonavir 100 mg én gang dagligt med mad, 2 timer før og mindst 10 timer
REYATAZ 300 mg with ritonavir 100 mg once daily with food, 2 hours before and at least 10 hours
8 Samtidigt administrerede
8 Co-administered medicinal
efter administration af H2- receptorantagonis - ten.
following the administration of an H2-receptor antagonist.
Protonpumpehæmmere Omeprazol 40 mg QD
Proton pump inhibitors Omeprazole 40 mg QD
atazanavir
2
administration af
REYATAZ/ ritonavir
2 timer ritonavir 100 mg QD)
ritonavir 100 mg QD)
efter omeprazol
omeprazole
(0, 35; 0, 45)
(0.35, 0.45)
(0, 38; 0, 51)
(0.38, 0.51)
(0, 29; 0, 41)
(0.29, 0.41)
REYATAZ / ritonavir og en protonpumpehæmmer
If the
atazanavir
combination of
frarådes.
1
Hvis kombinationen af
REYATAZ/ ritonavir
↓0, 70 *
hr after
↓0, 69 *
↓ 0.70*
(morgen):
↓ 0.69*
REYATAZ /
with a proton pump
efter omeprazaol
omeprazaole
(0, 57; 0, 86)
(0.57, 0.86)
(0, 58; 0, 83)
(0.58, 0.83)
(0, 54; 0, 88)
(0.54, 0.88)
ritonavir og proton -
inhibitor is judged
* Sammenligning med atazanavir 300 mg QD med ritonavir 100 mg QD
* When compared to atazanavir 300 mg QD with ritonavir 100 mg QD
pumpehæmmeren vurderes at være
unavoidable, close clinical monitoring is
Faldet i AUC, Cmax, og Cmin var ikke mindre når en øget dosis af REYATAZ/ ritonavir (400/ 100 mg én gang dagligt) blev tidsmæssigt adskilt fra omeprazol ved 12 timer.
The decrease in AUC, Cmax, and Cmin was not mitigated when an increased dose of REYATAZ/ ritonavir (400/ 100 mg once daily) was temporally separated from omeprazole by 12 hours.
Dette fald i optagelsen af atazanavir kan påvirke effekten af atazanavir negativt.
This decrease in atazanavir exposure might negatively impact the efficacy of atazanavir.
Interaktionsmekanismen er nedsat opløselighed af atazanavir da den intragastriske pH stiger med protonpumpehæmmere.
The mechanism of interaction is decreased solubility of atazanavir as intra-gastric pH increases with proton pump inhibitors.
4. 4).
recommended in combination with an increase in the dose of REYATAZ to 400 mg with 100 mg of ritonavir; doses of proton pump inhibitors comparable to omeprazole 20 mg should not be exceeded (see section 4.4).
Antacida og lægemidler indeholdende buffere ANTIKOAGULANTIA
Antacids and medicinal products containing buffers ANTICOAGULANTS
Plasmakoncentrationen af atazanavir kan falde hvis det gastriske pH øges ved samtidig administration af antacida, inklusive lægemidler med buffere, og REYATAZ/ ritonavir.
Reduced plasma concentrations of atazanavir may be the consequence of increased gastric pH if antacids, including buffered medicinal products, are administered with REYATAZ/ ritonavir.
REYATAZ / ritonavir bør administreres 2 timer inden eller 1 time efter antacida eller lægemidler med buffere.
REYATAZ/ ritonavir should be administered 2 hours before or 1 hour after antacids or buffered medicinal products.
Samtidig administration med REYATAZ/ ritonavir kan medføre fald eller, mindre hyppigt, stigning i INR (International Normalised Ratio).
Co-administration with REYATAZ/ ritonavir has the potential to produce a decrease or, less often, an increase in INR (International Normalised Ratio).
Det anbefales at monitorere INR omhyggeligt under behandling med REYATAZ / ritonavir, særligt når behandlingen påbegyndes.
It is recommended that the INR be monitored carefully during treatment with REYATAZ/ ritonavir, especially when commencing therapy.
ANTINEOPLASTISKE og IMMUNSUPPRIMERENDE MIDLER Antineoplastiske midler Irinotecan Immunsupprimerende midler
ANTINEOPLASTICS AND IMMUNOSUPRESSANTS Antineoplastics Irinotecan Immunosuppressants
Atazanavir hæmmer UGT og kan derfor interferere med irinotecan - metabolismen og medføre øget irinotecan- toksicitet.
Atazanavir inhibits UGT and may interfere with the metabolism of irinotecan, resulting in increased irinotecan toxicities.
Hvis REYATAZ / ritonavir administreres samtidig med irinotecan, bør patienten monitoreres tæt for irinotecan- relaterede bivirkninger.
If REYATAZ/ ritonavir is co-administered with irinotecan, patients should be closely monitored for adverse events related to irinotecan.
Ciclosporin Tacrolimus Sirolimus KARDIOVASKULÆRE MIDLER Antiarytmika
Cyclosporin Tacrolimus Sirolimus CARDIOVASCULAR AGENTS Antiarrhythmics
Koncentrationer af disse immunsupprimerende midler kan pga.
Concentrations of these immunosuppressants may be increased when co-administered with REYATAZ/ ritonavir due to CYP3A4 inhibition.
CYP3A4- hæmning øges ved samtidig administration med REYATAZ/ ritonavir.
Concentrations of these antiarrhythmics may be increased when co-administered with REYATAZ/ ritonavir.
Hyppigere monitorering af den terapeutiske koncentration af disse lægemidler anbefales indtil plasmaniveauerne er stabile.
Caution is warranted and therapeutic concentration monitoring is
Amiodaron, Systemisk lidocain, Kinidin Calcium- antagonister
Calcium channel blockers
Koncentrationer af disse antiarytmika kan øges ved samtidig administration med REYATAZ/ ritonavir.
contraindicated due to potential inhibition of CYP3A by REYATAZ/ ritonavir.
Der bør udvises forsigtighed, og monitorering af terapeutiske koncentrationer anbefales, hvis dette er muligt.
recommended when available.
4. 3).
The concomitant use of quinidine is contraindicated (see section 4.3).
Bepridil
Bepridil
REYATAZ/ ritonavir bør ikke anvendes i kombination med lægemidler, der er substrater af CYP3A4 og som har et snævert terapeutisk indeks.
REYATAZ/ ritonavir should not be used in combination with medicinal products that are substrates of CYP3A4 and have a narrow therapeutic index.
4. 3)
Co-administration with bepridil is contraindicated (see section 4.3)
↑2, 25 ↑1, 98 ↑2, 42 diltiazem
↑ 2.25 ↑ 1.98 ↑ 2.42 diltiazem
En initial dosis -
An initial dose
(2, 09; 2, 41 (1, 78; 2, 19) (2, 14; 2, 73) desacetyl - ↑2, 65 ↑2, 72 ↑2, 21 diltiazem (2, 45; 2, 87) (2, 44; 3, 03) (2, 02; 2, 42)
(2.09, 2.41 (1.78, 2.19) (2.14, 2.73) desacetyl- ↑ 2.65 ↑ 2.72 ↑ 2.21 diltiazem (2.45, 2.87) (2.44, 3.03) (2.02, 2.42)
reduktion af diltiazem på 50% anbefales med efterfølgende titrering efter behov og EKG -
reduction of diltiazem by 50% is recommended, with subsequent titration as
Der er ikke set signifikant påvirkning af atazanavir- koncentrationen.
No significant effect on atazanavir concentrations was observed.
Der sås stigning i maksimalt PR- interval sammenlignet med atazanavir alene.
There was an increase in the maximum PR interval compared to atazanavir alone.
Samtidig administration af diltiazem og REYATAZ/ ritonavir er ikke undersøgt.
Co-administration of diltiazem and REYATAZ/ ritonavir has not been studied.
Interaktionsmekanismen for diltiazem/ atazanavir er CYP3A4- hæmning.
The mechanism of diltiazem/ atazanavir interaction is CYP3A4 inhibition.
monitorering
needed and ECG monitoring
Verapamil KORTIKOSTEROIDER
Verapamil CORTICOSTEROIDS
CYP3A4- hæmning.
Serum concentrations of verapamil may be increased by REYATAZ/ ritonavir due to CYP3A4 inhibition..
Der bør udvises forsigtighed ved samtidig administration af verapamil og REYATAZ / ritonavir
Caution should be exercised when verapamil is co-administered with REYATAZ/ ritonavir
Fluticasonpropionat intranasalt 50 µg, 4 gange dagligt i 7 dage (ritonavir 100 mg kapsler BID) EREKTIL DYSFUNKTION PDE5- hæmmere
Fluticasone propionate intranasal 50 µg 4 times daily for 7 days (ritonavir 100 mg capsules BID) ERECTILE DYSUNCTION PDE5 Inhibitors
Større effekt kan forventes ved inhalation af fluticasonpropionatet.
The fluticasone propionate plasma levels increased significantly, whereas the intrinsic cortisol levels decreased by approximately 86% (90% confidence interval 82-89%) Greater effects may be expected when fluticasone propionate is inhaled.
Systemiske bivirkninger af kortikosteroidet, inklusive Cushings syndrom og adrenal suppression, er indberettet hos patienter behandlet med ritonavir og inhaleret eller intranasalt administreret fluticasonpropionat; dette kan også forekomme med andre kortikosteroider, der metaboliseres via P450 3A, fx budesonid.
Systemic corticosteroid effects including Cushing’ s syndrome and adrenal suppression have been reported in patients receiving ritonavir and inhaled or intranasally administered fluticasone propionate; this could also occur with other corticosteroids metabolized via the P450 3A pathway, eg, budesonide.
Det vides endnu ikke hvordan høj systemisk optagelse af fluticason påvirker plasma- niveauer af ritonavir.
The effects of high fluticasone systemic exposure on ritonavir plasma levels are yet unknown.
4. 4).
Co-administration of REYATAZ/ ritonavir and these glucocorticoids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects (see section 4.4).
Dosisreduktion af glukokortikoidet bør overvejes, og patienten bør monitoreres tæt for lokale og systemiske bivirkninger eller skiftes til et glukokortikoid, som ikke er et substrat for CYP3A4 (fx beclomethason).
A dose reduction of the glucocorticoid should be considered with close monitoring of local and systemic effects or a switch to a glucocorticoid, which is not a substrate for CYP3A4 (eg, beclomethasone).
Derudover kan det i tilfælde af seponering af glukokortikoidet, være nødvendigt med progressiv dosisreduktion over en længere periode.
Co-administration with REYATAZ/ ritonavir may result in increased concentrations of sildenafil and an increase in sildenafil-associated adverse events, including hypotension, visual changes, and priapism.
10
St.
Samtidigt administrerede
10 Co-administered medicinal
vedrørende samtidig administration
concerning
Sildenafil
co-administration
Sildenafil metaboliseres af CYP3A4.
This effect may be due to an induction of CYP3A4.
Interaktionsmekanismen for sildenafil/ atazanavir er CYP3A4- hæmning.
There is a risk of loss of therapeutic effect and development of resistance (see section 4.3).
Prikbladet perikum (Hypericum perforatum):
with products containing St.
HORMONEL ANTIKONCEPTION
John's wort is contraindicated.
Denne effekt kan skyldes en induktion af CYP3A4.
HORMONAL CONTRACEPTIVES
Ethinyløstradiol 35 μg + norethindron (atazanavir 400
Ethinyloestradiol 35 μ g + norethindrone (atazanavir 400
Samtidig administration of
The co-administration of
mg QD) LIPIDSÆNKENDE MIDLER HMG- CoA- reduktasehæmmere
mg QD) LIPID LOWERING AGENTS HMG-CoA reductase inhibitors
Koncentrationen af det orale antikonceptionsmiddel øges på grund af UGT- hæmning.
The concentration of oral contraceptives was increased due to UGT inhibition.
I modsætning hertil kan ritonavir nedsætte koncentrationen af ethinyløstradiol.
In contrast, ritonavir may decrease ethinyloestradiol concentrations.
Virkningen af samtidig administration af oral antikonception og REYATAZ/ ritonavir er ikke undersøgt.
The effects of co-administration of oral contraceptives and REYATAZ/ ritonavir have not been studied.
4. 4).
REYATAZ/ ritonavir and oral contraceptives should be avoided (see section 4.4).
Andre pålidelige antikonceptions - metoder bør overvejes.
Alternate reliable methods of contraception should be considered.
Simvastatin Lovastatin
Simvastatin Lovastatin
Simvastatin og lovastatin er i høj grad afhængige af CYP3A4 til metabolisering, og samtidig administration med REYATAZ/ ritonavir kan medføre øgede koncentrationer.
Simvastatin and lovastatin are highly dependent on CYP3A4 for their metabolism and co-administration with REYATAZ/ ritonavir may result in increased concentrations.
Samtidig administration af simvastatin eller lovastatin og REYATAZ / ritonavir frarådes på grund af øget risiko for myopati, inklusive rhabdomyolyse.
Co-administration of simvastatin or lovastatin with REYATAZ/ ritonavir is not recommended due to an increased risk of myopathy including rhabdomyolysis.
Brug af anden HMG- CoA - hæmmer, som ikke metaboliseres via CYP3A, fx pravastatin eller fluvastatin, anbefales.
The use of another HMG- CoA reductase inhibitor which does not undergo metabolism by CYP3A such as pravastatin or fluvastatin is recommended.
Atorvastatin OPIOIDS
Atorvastatin OPIOIDS
Risiko for myopati, inklusive rhabdomyolyse, kan også øges med atorvastatin, som også metaboliseres via CYP3A4.
The risk of myopathy including rhabdomyolysis may also be increased with atorvastatin, which is also metabolised by CYP3A4.
Buprenorphin, QD, stabil vedligeholdesesdosis,
Buprenorphine, QD, stable maintenance dose,
buprenorphin ↑1, 67 ↑1, 37 ↑1, 69
buprenorphine ↑ 1.67 ↑ 1.37 ↑ 1.69
Samtidig administration kræver
Co-administration warrants
(atazanavir 300 mg QD med ritonavir 100 mg QD)
(atazanavir 300 mg QD with ritonavir 100 mg QD)
Interaktionsmekanismen er CYP3A4 - og UGT1A1- hæmning.
norbuprenorphine ↑ 2.05 ↑ 1.61 ↑ 2.01 The mechanism of interaction is CYP3A4 and UGT1A1 inhibition.
Atazanavir- koncentrationen påvirkes ikke i betydelig grad.
Concentrations of atazanavir were not significantly affected.
kognitiv påvirkning.
clinical monitoring for sedation and cognitive effects.
Dosisreduktion af buprenorphin kan overvejes.
A dose reduction of buprenorphine may be considered
Metadon, stabil vedligeholdelsesdosis (atazanavir 400 mg QD) SEDATIVER Benzodiazepiner
Methadone, stable maintenance dose (atazanavir 400 mg QD) SEDATIVES Benzodiazepines
Der er ikke set betydelig påvirkning af metadon- koncentrationen.
No significant effect on methadone concentrations was observed.
Da lav dosis af ritonavir (100 mg BID) er vist ikke at have betydelig effekt på metadon- koncentrationen, forventes på baggrund af disse data ingen interaktion ved samtidig administration af metadon og REYATAZ/ ritonavir.
Given that low dose ritonavir (100 mg twice daily) has been shown to have no significant effect on methadone concentrations, no interaction is expected if methadone is co-administered with REYATAZ and ritonavir, based on these data.
Dosisjustering er ikke nødvendig ved samtidig administration af metadon og REYATAZ / ritonavir.
No dosage adjustment is necessary if methadone is coadministered with REYATAZ and ritonavir.
Samtidig administration med REYATAZ/ ritonavir kan medføre en stor stigning i koncentrationen af disse benzodiazepiner.
Co-administration with REYATAZ/ ritonavir may cause a large increase in the concentration of these benzodiazepines.
Der er ikke gennemført interaktionsstudier af samtidig administration af
No drug interaction study has been performed for the co-administration of REYATAZ/ ritonavir with benzodiazepines.
REYATAZ / ritonavir bør ikke administreres sammen med triazolam eller
If REYATAZ is
Hvis REYATAZ administreres sammen med parenteral midazolam, bør dette foregå på en intensiv afdeling eller tilsvarende afdeling, som sikrer tæt klinisk monitorering og relevant medicinsk behandling i tilfælde af respiratorisk depression og/ eller forlænget sedering.
co-administered with parenteral midazolam, it should be done in an intensive care unit (ICU) or similar setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/ or prolonged sedation.